Biotech gets $12M to work on amped-up herbal anti-inflammatory

Biotech upstart Trino Therapeutics, a spinout of Ireland's Trinity University, has raised $12 million to get started on a new drug for inflammatory diseases. The biotech's scientific founders are using insights on a Chinese herbal remedy to develop a new treatment--PH46A--for inflammatory bowel disease, or IBD. Fountain Healthcare Partners, an Irish VC group, joined the Wellcome Trust in the initial round for Trino, which now has the cash to get through Phase IIa as it seeks a collaborator. Story


Suggested Articles

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.

Grid Therapeutics is planning to start trials of its lead cancer immunotherapy GT103 next year after raising $5 million in second-round financing.

The IPO comes as the Flagship startup prepares to test its lead inflammatory disease and anticancer microbial strains in humans.